Received Mar 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 4 | Unknown | PO / MO |
The patient took second dose of Vivotif, five days after the first dose; Case reference number US-BN-2024-00092 is a spontaneous case report initially received from a pharmacist via Med Communications (reference number: USBAV24-0141) on 22-Jan-2024 and concerns a male patient of unspecified age. The patient's medical history and concomitant medication details were not provided. On unspecified date, the patient took the first dose of Vivotif (batch number: unknown), at an unknown dose, orally, for unknown indication. On unspecified date, as reported five days after the first dose of Vivotif, the patient took the second dose of Vivotif (batch number: unknown), at an unknown dose, orally (explicitly coded as 'inappropriate schedule of vaccine administered'). On an unspecified dates, as reported every other day, the patient took the third and the fourth dose of Vivotif (batch number: unknown), at an unknown dose, orally. At the time of the initial report, it was unknown if the patient experienced any adverse event due to Vivotif vaccine. No further information was provided.; Reporter's Comments: A male patient of unspecified age took the second dose of Vivotif five days after the first dose for an unknown indication, which is considered as inappropriate schedule of vaccine administered. No associated adverse events were reported. Inappropriate schedule of vaccine administered is listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of vaccine administered is not related to Vivotif, but to a human factor. The case is non-serious.; Sender's Comments: A male patient of unspecified age took the second dose of Vivotif five days after the first dose for an unknown indication, which is considered as inappropriate schedule of vaccine administered. No associated adverse events were reported. Inappropriate schedule of vaccine administered is listed per company convention. The patient's medical history and concomitant medication details were not provided. Inappropriate schedule of vaccine administered is not related to Vivotif, but to a human factor. The case is non-serious.
Comments: None